297 related articles for article (PubMed ID: 35231699)
1. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
[TBL] [Abstract][Full Text] [Related]
2. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
[TBL] [Abstract][Full Text] [Related]
3. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
6. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
7. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
8. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis IA; Digklia A
Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
[TBL] [Abstract][Full Text] [Related]
10. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
11. Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction.
Ziogas DC; Papadopoulou E; Gogas H; Sakellariou S; Felekouras E; Theocharopoulos C; Stefanou DT; Theochari M; Boukovinas I; Matthaios D; Koumarianou A; Zairi E; Liontos M; Koutsoukos K; Metaxa-Mariatou V; Kapetsis G; Meintani A; Tsaousis GN; Nasioulas G
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201431
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
13. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
14. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
15. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
[TBL] [Abstract][Full Text] [Related]
16. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
17. Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing.
He Y; Huang W; Tang Y; Li Y; Peng X; Li J; Wu J; You N; Li L; Liu C; Zheng L; Huang X
Front Oncol; 2023; 13():1167144. PubMed ID: 37313463
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
20. Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients.
Xiong A; Ma N; Wei G; Li C; Li K; Wang B
Am J Cancer Res; 2021; 11(9):4551-4567. PubMed ID: 34659905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
